Gamida Cell garners $16M in VC

Israel's Gamida Cell $16 million dollars in a fourth round led by Israel Healthcare Ventures. Elscint Biomedical Investment, Denali Ventures, Biomedical Investments and TEVA Pharmaceuticals also participated in the round. The money will be used to expand Gamida Cell's tissue regeneration product pipeline (including a cardiac regeneration product), the planned clinical testing of the company's flagship product StemEx, and the ongoing pre-clinical development of products.

- see the release on the venture round

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.